42nd week of 2012 patent applcation highlights part 34 |
Patent application number | Title | Published |
20120263689 | ADIPOSE-DERIVED INDUCED PLURIPOTENT STEM CELLS - Methods and compositions for generating adipose-derived induced pluripotent stem cells for humans and animals and their use are provided. | 2012-10-18 |
20120263690 | BIOCONTROL MICROORGANISMS - Methods, devices, and compositions described herein are directed to artificially evolving an organism for use as a biocontrol agent. Methods, devices, and compositions described herein are useful for evolving a microorganism to acquire traits not naturally associated with the microorganism. The artificial evolution process can utilize culture methods and devices designed to accommodate particular culture methods described herein. The organism can be artificially evolved for a characteristic such as ultraviolet light tolerance, chemical tolerance, thermotolerance, enhanced growth rate on a target carbon source, host specific growth, modified sporulation characteristics or modified spores. | 2012-10-18 |
20120263691 | MODULAR APTAMER-REGULATED RIBOZYMES - An extensible RNA-based framework for engineering ligand-controlled gene regulatory systems, called ribozyme switches, that exhibit tunable regulation, design modularity, and target specificity is provided. These switch platforms typically contain a sensor domain, comprised of an aptamer sequence, and an actuator domain, comprised of a hammerhead ribozyme sequence. A variety of modes of standardized information transmission between these domains can be employed, and this application demonstrates a mechanism that allows for the reliable and modular assembly of functioning synthetic hammerhead ribozyme switches and regulation of ribozyme activity in response to various effectors. In some embodiments aptamer-regulated cis-acting hammerhead ribozymes are provided. | 2012-10-18 |
20120263692 | Engineered Xenogeneic Cells for Repair of Biological Tissue - A transplant system and method including at least one cell from a xenogeneic donor to be transplanted into a host. The at least one cell is adapted to include a gene that causes expression of a protein that suppresses or prevents an immune response of the host to the at least one cell. | 2012-10-18 |
20120263693 | Methods for Treating Progressive Multifocal Leukoencephalopathy (PML) - The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes. | 2012-10-18 |
20120263694 | Intimate Lubrication Kit - The kit comprises applicators of lubricating composition for use during the days up to and including ovulation and applicators of a slightly thicker composition for use just after ovulation. | 2012-10-18 |
20120263695 | COMPOSITION HAVING STRAINS OF LACTOBACILLUS FERMENTUM - The invention relates to a pharmaceutical and/or dietetic composition for increasing the impact of the immune defense of higher living beings, wherein bacteria of the species | 2012-10-18 |
20120263696 | Indirect Substrates for Microorganisms Metabolizing 1,2-Propanediol - The present invention relates generally to enhanced activity of certain probiotics. The increased efficacy is achieved by using certain substrate components that indirectly supply the probiotics with a specific source of energy. The substrate components are specifically designed to stimulate 1,2-propanediol production. | 2012-10-18 |
20120263697 | HERBAL CATTLE FEED SUPPLEMENT COMPOSITIONS FOR ENHANCING PRODUCTIVITY AND QUALITY OF MILK - The present invention relates to multi purpose herbal cattle feed supplement compositions for enhancing the productivity and quality of milk by improved bioavailability/bioenhancing of nutrients. The herbal composition comprises an effective amount of an extract and/or at least one bioactive fraction or powder from herbs such as | 2012-10-18 |
20120263698 | Treatment of Neurodegenerative Disease - A method for reducing alpha-synuclein amyloid protein in a patient suffering from Parkinson's Disease comprising administering to the patient an effective amount of trans-resveratrol, a method for treating a neurodegenerative disease associated with amyloid proteins comprising administering to a patient in need thereof an effective amount of trans-resveratrol, and a method for treating Parkinson's Disease comprising administering to a patient in need thereof a pharmaceutically effective amount of carbidopa, levodopa, and trans-resveratrol are described. More particularly, the effect of trans-resveratrol on reducing the pharmaceutically effective dose of at least one of carbidopa and levodopa in the treatment of Parkinson's Disease is described. In addition, a method of improving cognition, speech and/or movement in a patient suffering from Parkinson's Disease comprising administering to the patient carbidopa, levodopa and trans-resveratrol is described. | 2012-10-18 |
20120263699 | Compositions and Methods for Preservation of Fresh Produce - The present invention is concerned with compositions and methods for treatment of fresh produce to reduce the levels of bacterial and/or fungal contamination. The compositions comprise the ingredients selected from a source of chlorite ions, enzymes, grapefruit seed extract, and an agent for adjusting the pH of the composition, and a pH buffering system to maintain a stable pH. The methods of preserving produce include applying the compositions to produce, to the trees or plants that bear produce, or to the packing materials used to pack, ship and sell the produce. | 2012-10-18 |
20120263700 | HUMAN CYSTATHIONINE BETA-SYNTHASE VARIANTS AND METHODS OF PRODUCTION THEREOF - Human cystathionine β-synthase variants are disclosed, as well as a method to produce recombinant human cystathionine β-synthase and variants thereof. More particularly, the role of both the N-terminal and C-terminal regions of human CBS has been studied, and a variety of truncation mutants and modified CBS homologues are described. In addition, a method to express and purify recombinant human cystathionine β-synthase (CBS) and variants thereof which have only one or two additional amino acid residues at the N-terminus are described. | 2012-10-18 |
20120263701 | COAGULATION FACTOR VII COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising factor VII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions. | 2012-10-18 |
20120263702 | Human Aminoacyl-tRNA Synthetase Polypeptides Useful For The Regulation of Angiogenesis - Pharmaceutical compositions comprising truncated tryptophanyl-tRNA synthetase polypeptides useful for regulating angiogenesis an nucleic acids encoding such tRNA synthetase polypeptides are described. Methods of making and using such compositions are also disclosed. | 2012-10-18 |
20120263703 | COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising factor DC coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions. | 2012-10-18 |
20120263704 | POWDERY MALTED RICE EXTRACT COMPOSITION - Disclosed are an agent for promoting proliferation of lactic acid bacteria, a preservative, and others, all of which do not deteriorate the flavor of food products. Specifically disclosed is a powdery malted rice extract composition obtained by inoculating lactic acid bacteria in a liquid prepared from a water extract of malted rice so that its Brix degree is 0.01 to 10, culturing the bacteria in the liquid, followed by drying the resulting culture. | 2012-10-18 |
20120263705 | Managing and Treating Keloids - Methods of managing and treating a keloid in mammal are disclosed. An embodiment includes managing and treating a keloid by covering the keloid with flurandrenolide tape, applying graphites ointment on the keloid and applying witch hazel ointment on the keloid. A further embodiment includes covering the keloid with flurandrenolide tape; and removing the flurandrenolide tape from the keloid after 5 to 10 hours; and applying witch hazel ointment on the keloid; and applying capsaicin ointment on the keloid. Yet another embodiment comprises steps of making and providing a mixture including equal proportions by mass (or weight) of flurandrenolide, witch hazel, graphites and capsaicin; and applying the mixture on the keloid in a manner that includes covering the keloid with the mixture. | 2012-10-18 |
20120263706 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS - Enantiomerically pure compound of formula 1 | 2012-10-18 |
20120263707 | Broad Spectrum ErbB Ligand Binding Molecules and Methods for Preparing and Using Them - Chimeric ErbB ligand binding molecules having detectable binding activity for more ErbB ligands than any one of native ErbB 1, ErbB3 or ErbB4 are disclosed. Preferably, the binding molecules bind a broad spectrum and, more preferably, the full spectrum of ErbB ligands. The chimeric ErbB ligand binding molecules generally have a subunit LI derived from one of ErbB1, 3, or 4 and a subunit LII derived from another distinct ErbB receptor type. The sub-domain, SI, which joins LI and LII can be from either one of the receptor types or can have portions from both. Pharmaceutical compositions that contain the molecules and methods for the treatment of ErbB sensitive diseases are also disclosed. | 2012-10-18 |
20120263708 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS - The present invention relates to substituted aminoquinoxaline compounds of general formula (I) in which (II), R | 2012-10-18 |
20120263709 | USE OF IL-33 ANTAGONISTS TO TREAT FIBROTIC DISEASES - Methods for treating fibrotic disease, such as idiopathic pulmonary fibrosis and scleroderma, with antagonists of IL-33 are disclosed. | 2012-10-18 |
20120263710 | ADMINISTERING ANTI-PLACENTAL GROWTH FACTOR ANTIBODIES - The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF | 2012-10-18 |
20120263711 | Engineering Fc Antibody Regions to Confer Effector Function - The present invention relates to molecules having a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region. These modified molecules confer an effector function to a molecule, where the parent molecule does not detectably exhibit this effector function. In one embodiment, the variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention have particular utility in treatment, prevention or management of a disease or disorder, in a sub-population of patients, wherein the target antigen is expressed at low levels in the target cell population. | 2012-10-18 |
20120263712 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES - The present invention relates to a compound of formula (I) | 2012-10-18 |
20120263713 | Combination therapy of an afucosylated CD20 antibody with fludarabine and/or mitoxantrone - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone. | 2012-10-18 |
20120263714 | SUBSTITUTED HALOPHENOXYBENZAMIDE DERIVATIVES - The present invention relates to substituted halophenoxybenzamide derivative compounds of general formula (I) in which R | 2012-10-18 |
20120263715 | Topical Methods Of Treating RSV Infections And Related Conditions - The present invention provides methods for preventing, managing, treating and/or ameliorating a respiratory syncytial virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), and/or a symptom or a long-term respiratory condition relating thereto (e.g., asthma, wheezing, reactive airway disease (RAD), or chronic obstructive pulmonary disease (COPD)) in a human subject, comprising topically administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity and further comprise a modified IgG constant domain, or FcRn-binding fragment thereof, to not only decrease RSV infection, but also decrease the pro-inflammatory epithelial cell immune responses in order to mitigate the later development of asthma and/or wheezing and/or COPD in said patient. | 2012-10-18 |
20120263716 | METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD - The method of treating a person having a cancer selected from carcinoma, sarcoma or hematopoietic cancer by administering (a) an effective amount of at least one anti-cancer drug selected from the group consisting of an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor and a Raf kinase inhibitor and (b) an effective amount of 5-(4-(6-(4-amino-3,5-dimethyl-phenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy)-benzyl)-thiazolidine-2,4-dione.dihydrochloride provided that said carcinoma is not lung cancer when an EGFR inhibitor is erlotinib. The invention also provides a pharmaceutical composition that may be used in practicing said method. | 2012-10-18 |
20120263717 | HUMANIZED ANTI-FGF19 ANTAGONISTS AND METHODS USING SAME - The present invention concerns antagonists of the FGF19/FGFR4 pathways, and the uses of same. | 2012-10-18 |
20120263718 | BLOCKADE OF TL1A-DR3 INTERACTIONS TO AMELIORATE T CELL MEDIATED DISEASE PATHOLOGY AND ANTIBODIES THEREOF - Provided are methods and compositions for treating inflammatory autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. The interaction between DR3 and TL1A can be blocked by reducing expression of TL1A. The interaction between DR3 and TL1A can be blocked by administration of anti-DR3 antibodies. The interaction between DR3 and TL1A can be blocked by administration of anti-TL1A antibodies. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease (IBD). | 2012-10-18 |
20120263719 | COMPOSITIONS AND METHODS FOR TREATING ASPERGILLOSIS - The present invention provides monoclonal antibodies specific for members of the | 2012-10-18 |
20120263720 | Novel Therapeutic and Diagnostic Means - Disclosed is a method for treatment of HIV related diseases comprising targeting complexes between on the one hand the C5 domain of gp120 and on the other hand gp41 or the C2 domain of gp120. The complexes may be stabilised by administering compounds, such as antibodies, capable of directly interacting with and stabilising the complex, or by immunizing with C5 and gp41/C2 derived material so as to induce antibodies that bind to and stabilise the complex. | 2012-10-18 |
20120263721 | Therapeutic Combination and Methods of Treatment With a DLL4 Antagonist and an Anti-Hypertensive Agent - Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same. | 2012-10-18 |
20120263722 | Dual Variable Domain Immunoglobulins and Uses Thereof - Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 2012-10-18 |
20120263723 | c-Met Antibodies - Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met. | 2012-10-18 |
20120263724 | Escherichia coli o157:h7 proteins and uses thereof - Immunogenic | 2012-10-18 |
20120263725 | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV - The present invention relates to a pharmaceutical composition, comprising an activated-potentiated form of an antibody to CD4 receptor, and method of treating and preventing the diseases caused by HIV or associated with HIV, including AIDS. | 2012-10-18 |
20120263726 | Pharmaceutical composition and method of inhibiting of production or amplifying of elimination of P24 protein - The present invention relates to a pharmaceutical composition, comprising an activated-potentiated form of an antibody to CD4 receptor, and method of inhibiting of production or amplifying of elimination of P24 protein. | 2012-10-18 |
20120263727 | METHOD TO GENERATE ANTIBODIES TO ION CHANNELS - The present invention provides a method for generating a functionally modifying antibody to an ion channel comprising immunizing a host with a cyclic peptide comprising at least part of an extracellular sequence of said ion channel. | 2012-10-18 |
20120263728 | METHOD TO GENERATE ANTIBODIES TO ION CHANNELS - The present invention provides a method for generating a functionally modifying antibody to an ion channel comprising immunizing a host with a cyclic peptide comprising at least part of an extracellular sequence of said ion channel. | 2012-10-18 |
20120263729 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE - The invention pertains to methods of treating cardiovascular disease by modulating inflammatory and immunoregulatory responses associated with such pathological conditions. Embodiments of the invention provide methods for the treatment of cardiovascular disease in a subject having cardiovascular disease comprising administering an effective amount of one or more IL-17 antagonists, IL-18 antagonists, 4-1BB antagonists, CD30 antagonists, OX40 antagonists and/or CD39 alone or in any combination. This abstract is provided for the sole purpose of enabling the reader to quickly ascertain the subject matter of the technical disclosure and is not intended to be used to interpret or limit the scope or meaning of the claims. 37 CFR 1.72(b). | 2012-10-18 |
20120263730 | RECEPTORS OF RSPO2 AND RSPO3 - The present invention relates to the finding that Syndecans (Sdc) are receptors of Rspondin-2 (Rspo2) and Rspondin-3 (Rspo3). Thus, the present invention relates to the identification of Rspo2, Rspo3 and/or Sdc activity modulators by determining if a test compound has the ability to modulate the binding of an Rspo2 and/or Rspo3 polypeptide to an Sdc polypeptide. Further, the invention refers to novel uses for antagonists of Rspo2 and/or Rspo3 in the treatment of Sdc-associated disorders and for Sdc antagonists in the treatment of Rspo2- and/or Rspo3-associated disorders. | 2012-10-18 |
20120263731 | HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS - The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof. | 2012-10-18 |
20120263732 | CD40 ANTIBODY FORMULATION AND METHODS - The present invention provides a method of treating tumor in a patient comprising administering to said patient a CD40 agonist antibody according to an intermittent dosing schedule. The present invention also provides a method of treating tumor in a patient comprising administering a combination of a CD40 agonist antibody and a DNA replication inhibitor. Also provided is a formulation for use in the treatment. | 2012-10-18 |
20120263733 | ANTI-CXCL9, ANTI-CXCL10, ANTI-CXCL11, ANTI-CXCL13, ANTI-CXCR3 AND ANTI-CXCR5 AGENTS FOR INHIBITION OF INFLAMMATION - Methods for preventing or inhibiting inflammation in a subject are disclosed. In one aspect, the method comprises administering to a subject diagnosed with an inflammatory disease an effective amount of an anti-inflammatory agent that (1) inhibits the expression of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and/or CXCR5, or (2) inhibits the interaction between CXCR3 and CXCL9, CXCL10 or CXCL11, or between CXCR5 and CXCL13, or (3) inhibits a biological activity of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and/or CXCR5, wherein the agent comprises an antibody, antibody fragment, short interfering RNA (siRNA), aptamer, synbody, binding agent, peptide, aptamer-siRNA chimera, single stranded antisense oligonucleotide, triplex forming oligonucleotide, ribozyme, external guide sequence, or an agent-encoding expression vector. | 2012-10-18 |
20120263734 | Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus Infections - The present invention provides novel anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection. | 2012-10-18 |
20120263735 | SYNTHETIC IMMUNOGENIC GLYCOCONJUGATE FOR MELANOMA IMMUNOTHERAPY - The present invention refers to compounds of formula (I) as useful melanoma vaccines' active ingredients. As a matter of fact, compounds of formula (I) are immunogenic artificial antigens, mimetics of GM3 and GM3 lactone, well known tumor associated antigens (TAAs). In addition, the present invention refers to specific antibodies for compounds of formula (I) which are able to bind to the TAAs. The hereinabove reported compounds and antibodies are therefore potentially useful respectively for the active and passive immunization against tumors overexpressing GM3 ganglioside, in a preferred embodiment melanoma and colon cancer, and for their diagnosis and prognosis. | 2012-10-18 |
20120263736 | METHOD FOR PREDICTING AND TREATING A STERILE INFLAMMATION AND DISCRIMINATING BETWEEN STERILE AND INFECTIVE INFLAMMATION - The invention provides methods for predicting the likelihood that a subject will develop a sterile inflammation or will have an increased propensity to later develop a sterile inflammation, for determining whether a subject with tissue damage should be administered an antimicrobial agent (at full or a reduced dosage) or an anti-inflammatory agent, and for treating a subject with tissue damage. In the methods, an increased ratio of the amount of mitochondrial nucleic acid or peptide to the amount of microbial nucleic acid or peptide indicates a subject that has an increased likelihood of developing a sterile inflammation or an increased propensity to later develop a sterile inflammation, or a subject that should not be administered, or that should be administered at a reduced dosage, an antimicrobial agent or one or more anti-inflammatory agents and not an antimicrobial agent. Kits for detecting mitochondrial and/or microbial nucleic acids or peptides are provided. | 2012-10-18 |
20120263737 | METHODS FOR INHIBITING ALLOGRAFT REJECTION - Disclosed herein are methods for treating or inhibiting allograft rejection in a transplant recipient. In some embodiments, the methods include administering to the transplant recipient a first amount of a JAK1/3 inhibitor comprising 5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-one (Compound I) or a prodrug thereof and administering to the transplant recipient a second amount of a non-JAK1/3 inhibitor immunosuppressant, wherein the combined effect of the first amount and the second amount is greater than the effect of the first amount or the second amount individually, wherein the JAK1/3 inhibitor acts in combination with the non-JAK1/3 inhibitor immunosuppressant to inhibit or treat allograft rejection. In some embodiments at least one of the first amount or the second amount is individually a suboptimal dose for inhibiting or treating allograft rejection. In some examples, the combined effect of the first amount and the second amount to inhibit or treat allograft rejection in the transplant recipient is synergistic. | 2012-10-18 |
20120263738 | MULTIPLEX DICER SUBSTRATE RNA INTERFERENCE MOLECULES HAVING JOINING SEQUENCES - The present invention is based, in part, upon the insight that compound DsiRNA agents can be generated using site-specific RNase H-cleavable double-stranded nucleic acid regions to attach, e.g., one DsiRNA moiety to another DsiRNA moiety and/or one DsiRNA moiety to a functional group and/or payload. Because such double-stranded nucleic acid joining sequences are site-specifically RNase H-cleavable, the bifunctional molecule is cleaved into DsiRNAs bearing terminal ends that orient dicer cleavage. Detrimental impacts of administering a single double-stranded nucleic acid RNAi agent of longer than 30-35 nucleotides (e.g., provocation of interferon response) is minimized, as once administered to a subject or RNase H-containing cell, RNase H cleavage produces a shortened, active DsiRNA agent(s). The invention provides bifunctional DsiRNA agents that are joined by double-stranded DNA extension joining sequences, which do not provoke RNase H cleavage. | 2012-10-18 |
20120263739 | ANTI INTEGRIN ANTIBODIES LINKED TO NANOPARTICLES LOADED WITH CHEMOTHERAPEUTIC AGENTS - The invention relates to anti-integrin antibodies which are covalently linked to nanoparticles, wherein these nanoparticles were prior loaded with chemotherapeutic/cytotoxic agents. The antibody-chemotherapeutic agent-nanoparticle conjugates according to the invention, especially wherein the antibody is MAb DI17E6 and the cytotoxic agent is doxorubicin show a significant increase of tumor cell toxicity. | 2012-10-18 |
20120263740 | APTAMER-TARGETED SIRNA TO INHIBIT NONSENSE MEDIATED DECAY - Compositions for inducing or enhancing antigenicity of a target cell by modulating the non-sense mediated decay pathway in the target cell. The compositions comprise one or more aplamers providing specificity and delivery of an oligonucleotide to the target, These compositions have broad applicability in the treatment of many diseases. | 2012-10-18 |
20120263741 | VARIANTS OF THE MAJOR ALLERGEN PHL P 1 FROM TIMOTHY GRASS - The invention relates to pharmaceutically important variants of the major allergen Phl p 1 from timothy grass, characterised in that a preparation, hitherto not possible, of monomeric molecules which are soluble and stable in physiological media can be carried out with the aid of prokaryotic expression systems and subsequent purification thereof. | 2012-10-18 |
20120263742 | Combination of Protein Forms for Hornfly Vaccination - Thrombostasin is an anti-clotting protein found in saliva of | 2012-10-18 |
20120263743 | INFLUENZA HEMAGGLUTININ COMPOSITIONS AND USES THEREOF - The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions, vaccine compositions and pharmaceutical compositions for the treatment, amelioration and/or prevention of influenza. The compositions, vaccine compositions and pharmaceutical compositions of the invention comprise a virus-like particle of an RNA bacteriophage and at least one antigen, wherein said at least one antigen is an ectodomain of an influenza virus hemagglutinin protein or a fragment of said ectodomain of an influenza virus hemagglutinin protein. When administered to an animal, preferably to a human, said compositions, vaccine compositions and pharmaceutical compositions efficiently induce immune responses, in particular antibody responses, wherein typically and preferably said antibody responses are directed against influenza virus. Thus, the invention further provides methods of treating, ameliorating and/or preventing influenza virus infection. | 2012-10-18 |
20120263744 | Compositions And Methods Involving Respiratory Syncytial Virus Subgroup B Strain 9320 - The complete polynucleotide sequence of the human respiratory syncytial virus subgroup B strain 9320 genome is provided. Proteins encoded by this polynucleotide sequence are also provided. Isolated or recombinant RSV (e.g., attenuated recombinant RSV), nucleic acids, and polypeptides, e.g., comprising mutations in the attachment protein G, are also provided, as are immunogenic compositions comprising such isolated or recombinant RSV, nucleic acids, and polypeptides. Related methods are also described. | 2012-10-18 |
20120263745 | ANTICHLAMYDIAL AGENTS - An antichlamydial agent comprising an inhibitor of Chlamydial Protease-like Activity Factor (CPAF). The inhibitor of CPAF can comprise a CPAF inhibitory segment and can optionally include one or more additional residues or domains. Also provided are compositions comprising an inhibitor of CPAF, methods of identifying an inhibitor of CPAF, and methods of treating a | 2012-10-18 |
20120263746 | USE OF AN L3 AND/OR L5 SOURCE AS A VACCINE OR AS A DIAGNOSTIC FOR A PARASITIC DISEASE - The invention relates to composition comprising an L3 and/or an L5 source and optionally an adjuvant for the preparation of a medicine for the treatment or prevention of a parasitic disease and to its diagnostic use of said parasitic disease. | 2012-10-18 |
20120263747 | Albumin-Fused Anti-Angiogenesis Peptides - The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as ‘albumin fusion proteins of the invention.’ These fusion proteins are herein collectively referred to as ‘albumin fusion proteins of the invention.’ These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor aniogenesis induced cell fusion. The invention further relates to compositions and methods preventing growth of, or promoting regression of, primary tumors and metastases; and for treating cancer, diabetic retinophathy, progressive macular degeneration or rheumatoid arthritis. | 2012-10-18 |
20120263748 | Superior Molecular Vaccine Linking the Translocation Domain of a Bacterial Toxin to an Antigen - Nucleic acids encoding a chimeric or fusion polypeptide which polypeptide comprises a first domain comprising a translocation polypeptide; and a second domain comprising at least one antigenic peptide are disclosed. The preferred translocation polypeptide is a bacterial toxin translocation polypeptide, such as domain II of | 2012-10-18 |
20120263749 | POLYVALENT CONJUGATE VACCINE FOR CANCER - This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Le | 2012-10-18 |
20120263750 | RECOMBINANT MODIFIED VACCINIA ANKARA (MVA) VACCINIA VIRUS CONTAINING RESTRUCTURED INSERTION SITES - The present invention relates to recombinant modified vaccinia Ankara (MVA) virus containing restructured sites useful for the integration of heterologous nucleic acid sequences into an intergenic region (IGR) of the virus genome, where the IGR is located between two adjacent, essential open reading frames (ORFs) of the vaccinia virus genome, wherein the adjacent essential ORFs are non-adjacent in a parental MVA virus used to construct the recombinant MVA virus, and to related nucleic acid constructs useful for inserting heterologous DNA into the genome of a vaccinia virus, and further to the use of the disclosed viruses as a medicine or vaccine. | 2012-10-18 |
20120263751 | Recombinant Measles Virus Useful as a Bivalent Vaccine Against Measles and Nipah Infections - Provided herein is a vaccine which is safe and effective against Nipah virus infection and a vector which is used in the manufacture of this vaccine and to provide a bivalent vaccine which exhibits an excellent preventive effect against measles virus and Nipah virus infection and which eliminates complexity at the time of inoculation. Also provided is a recombinant measles virus in which is inserted a gene which encodes a protein involved in preventing Nipah infection into the measles virus genome. The protein involved in preventing Nipah virus infection is preferably G protein or F protein which is a membrane protein. Also provided is a bivalent vaccine against measles and Nipah virus infection which contains the recombinant measles virus. Also provided is a method of manufacturing a vaccine against Nipah virus infection | 2012-10-18 |
20120263752 | Herpes Simplex Virus Vaccines - The present invention is directed to Herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes. | 2012-10-18 |
20120263753 | BENZONAPHTHYRIDINE-CONTAINING VACCINES - The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) polymeric particles and (c) a benzonaphthyridine compound, which compositions elicits an immune response when administered to a vertebrate subject. The invention also provides, inter alia, methods of producing immunogenic compositions and methods for using immunogenic compositions (e.g., for treatment), among other benefits. | 2012-10-18 |
20120263754 | Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines - Provided herein are methods for inducing a specific immune response in a subject by administering to the subject an immunogenic composition comprising a recombinant expression vector, or a vector particle comprising the recombinant expression vector, which vector comprises a polynucleotide sequence that encodes an immunogen of interest. The methods further comprise administering an adjuvant composition either concurrently or sequentially with the immunogenic composition. | 2012-10-18 |
20120263755 | METHODS AND COMPOSITIONS FOR ELICITING AN IMMUNE RESPONSE AGAINST HEPATITIS B VIRUS - The present invention relates to immunization of hypo-responsive groups of individuals. In particular, the present invention provides methods and compositions for eliciting a potent immune response to hepatitis B virus in individuals in need thereof. | 2012-10-18 |
20120263756 | VACCINES CONTAINING CANINE PARVOVIRUS GENETIC VARIANTS - Canine parvovirus vaccines and diagnostics and methods for their use are provided. The vaccines are effective against emerging canine parvovirus variants. | 2012-10-18 |
20120263757 | COMPOSITION AND METHOD FOR DIAGNOSIS AND IMMUNOTHERAPY OF PROSTATE CANCER - A method and composition for the diagnosis of and treatment of prostate cancer including a recombinant AKAP-4 tumor-associated antigen loaded antigen presenting cell that generates an AKAP-4 specific cytotoxic T lymphocyte specific for one or more prostate cancer cells. | 2012-10-18 |
20120263758 | PET FOOD COMPOSITIONS INCLUDING PROBIOTICS AND METHODS OF MANUFACTURE AND USE THEREOF - The present invention encompasses pet food compositions that include one or more probiotic microorganisms, which are useful to improve the health of companion animals. For example, the invention encompasses pet food compositions including a probiotic, for example, | 2012-10-18 |
20120263759 | Coating Comprising An Elastin-Based Copolymer - A copolymer comprising a block of an elastin pentapeptide and method of making and using the copolymer are provided. The copolymer may be used as a coating on a stent. Methods of using a stent coated with the copolymer are also provided. | 2012-10-18 |
20120263760 | NOVEL FORMULATION OF METAXALONE - The present invention relates to methods for producing particles of metaxalone using dry milling processes as well as compositions comprising metaxalone, medicaments produced using metaxalone in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of metaxalone administered by way of said medicaments. | 2012-10-18 |
20120263761 | SHELF STABLE PHARMACEUTICAL DEPOT - A pharmaceutical depot includes a biodegradable polymer having a glass transition temperature of 20 degrees centigrade or less and at least 25% wt solid particles suspended in the biodegradable polymer. The pharmaceutical depot also includes a post-operative pain relieving therapeutic agent. | 2012-10-18 |
20120263762 | STABILISED PARTICLES COMPRISING 5-METHYL-(6S)-TETRAHYDROFOLATE - The present invention relates to small stabilised particles comprising a crystalline form of an alkaline earth metal salt of 5-methyl-(6S)-tetrahydrofolate and at least one protective agent. Such particles confer stability to the alkaline earth metal salt of 5-methyl-(6S)-tetrahydrofolate, and is conveniently incorporated in unit dosage forms, such as wafers. | 2012-10-18 |
20120263763 | REGENERATIVE MATERIALS - Methods of making tissue fillers are provided. In certain embodiments, the tissue is flake-like and has regenerative properties. | 2012-10-18 |
20120263764 | COMPOSITIONS AND METHODS FOR INHIBITING AND/OR MODULATING EFFECTOR T-CELLS INVOLVED IN INFLAMMATORY NEURODEGENERATIVE DISEASE - Provided are methods for treating inflammatory neurodegenerative diseases (e.g., multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, stroke/cerebral ischemia, head trauma, spinal cord injury, Huntington's disease, migraine, cerebral amyloid angiopathy, inflammatory neurodegenerative condition associated with AIDS, age-related cognitive decline; mild cognitive impairment and prion diseases in a mammal), or at least one symptom thereof in a subject by administering a therapeutic composition comprising at least one electrokinetically-altered fluids (e.g., electrokinetically-generated oxygen-enriched fluids) of the present invention. Particular aspects provide methods for inhibiting and/or modulating the function and/or activity of effector T-cells, and/or for cell-based tolerogenic therapy (e.g., by modulating development and/or function and/or activity of T | 2012-10-18 |
20120263765 | AGENTS FROM CELLS - A composition includes an isolated cell; at least one particle within said cell; and at least one active agent associated with the particle, wherein the active agent is capable of being released from the cell. A method includes administration of such a cell to a subject. | 2012-10-18 |
20120263766 | Formulations - In a metered dose inhaler, comprising a canister and metering valve, containing a suspension aerosol formulation comprising particles of formoterol fumarate dihydrate and fluticasone propionate suspended in an HFA propellant, a method of reducing deposition of particles on the surfaces of the canister and the metering valve, the method comprising the step of adding a wetting agent to the formulation. | 2012-10-18 |
20120263767 | MAKEUP COMPOSITION COMPRISING A BLACK COLOUR MIXTURE OF PIGMENTS - The invention relates to cosmetic compositions comprising a black colour subtractive mixture consisting of at least one blue organic pigment, at least one yellow organic pigment and at least one red organic pigment, which are mixed homogeneously, said mixture having a luminance value L*(15°) of less than 30. | 2012-10-18 |
20120263768 | PHOTOPROTECTIVE COMPOSITION BASED ON A 2-ALKOXY-4-ALKYL KETONE PHENOL COMPOUND; USE OF SAID COMPOUND FOR INCREASING THE SUN PROTECTION FACTOR - The present invention relates to a fluid composition intended for protecting the skin and/or hair against ultraviolet radiation, characterized by the fact that it comprises, in a cosmetically acceptable aqueous support, at least: (a) one photoprotective system capable of screening out UV radiation; and (b) one 2-alkoxy-4-alkyl ketone phenol compound. The present invention also relates to the use of a 2-alkoxy-4-alkyl ketone phenol compound in a composition comprising, in a cosmetically acceptable medium, at least one photoprotective system capable of screening out UV radiation. | 2012-10-18 |
20120263769 | Ultraviolet Absorber-Including Clay Mineral And Cosmetics Containing The Same - The present invention provides an ultraviolet absorber-including clay mineral, which allows an ultraviolet absorber to be blended, as a powder component, into cosmetic preparations, can effectively absorb a wide range of ultraviolet light, and has excellent inclusion amount and inclusion strength; and cosmetics containing the same. The ultraviolet absorber-including clay mineral is characterized in that a polybase and an anionic ultraviolet absorber are intercalated between the layers of a water-swellable clay mineral. The polybase is preferably a polymer having a nitrogen-containing group that can become a cation. The anionic ultraviolet absorber is preferably one or more selected from 2-phenylbenzimidazole-5-sulfonic acid, 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid, and their sodium salts. | 2012-10-18 |
20120263770 | ANTI-ATOPIC DERMATITIS TEXTILES - The present invention relates to anti-atopic textiles, including a textile body and skin care layers formed by dyeing the textile body with a dyebath, obtained by filtering a mixture of earthworm powder and water through Korean paper. When clothes are made of the anti-atopic textiles and brought in contact with the skin, atopic dermatitis can be significantly alleviated because a moisturizing action and an anti-inflammation action are accelerated by a body composition and fluid components of earthworms included in the skin care layers and paper mulberry extract mixed from Korean paper. The anti-atopic textiles according to the present invention includes a textile body and skin care layers formed by dyeing the textile body with a dyebath which is obtained by mixing earthworm powder, obtained by pulverizing earthworms and drying the pulverized earthworms, and water and then filtering the mixture through Korean paper. | 2012-10-18 |
20120263771 | FIBER WITH MICROBIAL REMOVAL, MICRO-BIOCIDAL, OR STATIC GROWTH CAPABILITY - The fiber structures in the form of a fiber (or fiber mass), woven or nonwoven fabric, fiber absorbent layers, mats or bats or other collection of fiber can be modified to be microbiocidal, bacteriostatic, obtain immobilized, microbes, etc. The disclosed fiber has the unique ability to capture and hold microbes or microbial generating units within the fiber mass. | 2012-10-18 |
20120263772 | Pesticide Strips for Control of Mites in Honeybees - Pesticide strips used to control parasitic mites in honeybees. The pesticide strips are designed to have a lifetime or period of existence, after which the strip no longer exists in its original form. The strip breaks down, such as by disintegration, dissolving, decomposition, being eaten or carrier away, or otherwise degrading over time, so that at the end of the recommended lifetime, the strip is no longer in its original form. In most embodiments, at least 50% of the strip is no longer present, and in other embodiments at least 75% of the strip is no longer present. Preferably, at the end of the recommended lifetime, the strip no longer exists, at least the body of the strip that included the active ingredient. With this design, the strip does not provide extended low-dose pesticide that can be detrimental in treating the mites. | 2012-10-18 |
20120263773 | INSECT ATTRACTANTS AND THEIR USE IN METHODS OF INSECT CONTROL - The present invention utilizes a fatty acid as an attractant in a method of attracting whiteflies. By using a fatty acid as a whitefly attractant, it is possible to attract whiteflies to a desired location. The fatty acid can be used in a lure or other propagator to provide a dispersion of fatty acid in the air, the variation in the concentration of the fatty acid in the air being such that a whitefly is attracted to the lure as the source of the fatty acid. The use of a fatty acid as an attractant results in significantly higher levels of attraction, as measured by the number of whiteflies attracted to a sticky trap, as compared to the use of colour alone. | 2012-10-18 |
20120263774 | POLYMER COMPOSITION AND MOLDED ARTICLES SHAPED OF THE SAME - The present invention relates to a polymer composition comprising 100 parts by weight of an olefin-based polymer, and 0.01 to 100 parts by weight of an ester having a HLB value of 4 or less and 0.01 to 200 parts by weight of a releasable active compound per 100 parts by weight of said olefin-based polymer. | 2012-10-18 |
20120263775 | PRODUCTION OF PESTICIDE GRANULATES IN A SPOUTED BED APPARATUS - The present invention relates to a method for producing granules comprising a pesticide, comprising the spraying-on of a pesticide-containing spray liquid in the region of a near-circular gas/material stream of a spouted-bed apparatus onto the particle surface of the material, and the drying and granulation in the gas stream. Furthermore, the invention relates to granules comprising a pesticide, obtainable by said method, where the granules have a roundness of at least 0.85. | 2012-10-18 |
20120263776 | Method For Obtaining Non-Water-Soluble Powders Having Antimicrobial Activity, The Powders Thus Obtained and The Antibacterial Use Thereof - A method for obtaining non-water-soluble powders comprising antimicrobial activity and having quaternary ammonium salts adhered thereto. The invention also includes the powders thus obtained and the use thereof as antibacterial agents. The invention enables the production of non-soluble organic or inorganic powders having a particle size of 5 to 500 μm, having a quaternary ammonium salt adhered to the surface thereof and fixed on the surface. When deposited on textile materials, the powders enable bacterial and viral decontamination, by means of filtration, of polluted water or aqueous environments. Textile materials impregnated with powders according to the invention can be used in the production of breathing masks, protective garments or other items, in particular in a hospital environment. The antibacterial properties of the powders are at least twice as high as the antibacterial properties of the same quaternary ammonium salt used in isolation. | 2012-10-18 |
20120263777 | RECYCLABLE POROUS BEAD - SATELLITE NANOPARTICLE COMPOSITE AND FABRICATION METHOD THEREOF - An environment-friendly porous bead-satellite nanoparticles composite which has excellent recovery and repeated usage performance and can be used as a catalyst, an antiviral agent, or an antimicrobial, and a fabrication method thereof are provided. The porous bead-satellite nanoparticles composite includes a porous bead, a molecule having a first end coupled to the surface of the porous bead and including a functional group at a second end, and satellite nanoparticles coupled to the functional group, wherein the porous bead may have a core-shell structure including a cluster core of nanoparticles and a porous bead shell covering the cluster core. | 2012-10-18 |
20120263778 | POLYURETHANE UREA FOR STENT COATINGS - The invention relates to a polyurethane urea comprising structural units of formula (I), not terminated by at least one copolymer unit of polyethylene oxide and polypropylene oxide, and that can particularly be used for producing stent coatings. The invention further relates to a substrate having a base coating made of a polyurethane urea according to the invention. The invention further relates to a coating structure comprising at least one layer comprising active substances and made of a polyurethane urea according to the invention, and at least one layer free of active substances, made of a polyurethane urea according to the invention. The invention finally relates to a method for coating a substrate, wherein at least one layer made of a polyurethane urea according to the invention is applied to the substrate. | 2012-10-18 |
20120263779 | BIODEGRADABLE DRUG DELIVERY SYSTEM - A drug delivery system (DDS) comprised of segmented biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The segmented implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer, and permit the DDS to have segments that possess individual and different drug release characteristics. | 2012-10-18 |
20120263780 | Carbohydrate Entrapped Active Agent Delivery Composition and Articles Using the Same - Delivery compositions and substrates for imparting a volatile active agent to a surface are disclosed herein. To achieve the delivery of the volatile component, a delivery composition of a carbohydrate matrix and a volatile component is incorporated into the carbohydrate matrix to stabilize the volatile for extended periods of time. The delivery composition further comprises a self-generating expelling agent to expel the volatile component onto the contaminated surface or skin upon addition of a triggering agent. | 2012-10-18 |
20120263781 | METHODS AND COMPOSITIONS FOR TREATING RHINITIS - Improved efficacy in treatment of rhinitis with botulinum toxin is obtained using liposomal encapsulated botulinum formulations for administration of the botulinum toxin. The liposomes are typically administered in a physiologically acceptable carrier such as saline or phosphate buffered saline by instillation into the nasal passages. | 2012-10-18 |
20120263782 | METHODS AND COMPOSITIONS FOR TREATING HIV INFECTION - A method for treating latent HIV infection is disclosed. The method includes administering to a subject in need of such treatment an effective amount of an anti-IκBα agent, an anti-IκBε agent or both; and administering to the subject an effective amount of an antiviral agent. A pharmaceutical composition for treating latent HIV infection is also disclosed. | 2012-10-18 |
20120263783 | SINGLE MOLECULE NUCLEIC ACID NANOPARTICLES - The present technology relates to a nanoparticle platform based on the unique and varied properties of DNA. Circular DNA can be replicated using a strand displacing polymerase to generate long linear concatamers of controllable length that spontaneously fold into a ball conformation due to internal base-pairing. These balls of DNA are discreet particles that can be made in variable sizes on a nanometer size scale in a scalable manner. The particles can be used in a variety of manners, discussed herein, including specific targeting, drug delivery to cancer cells, and diagnostics. Nanoparticles may also serve as multifunctional platforms for the integration of many currently used cancer therapeutic techniques. | 2012-10-18 |
20120263784 | EMERGENCY CONTRACEPTIVE - The present invention discloses an emergency contraceptive formulation for nasal and/or pulmonary administration comprising of levonorgestrel optionally in combination with ethylestradiol. The said formulation can be in form of solution, suspension or carrier based systems selected from microemulsion and liposomes. | 2012-10-18 |
20120263785 | STABLE CANNABINOID COMPOSITIONS AND METHODS FOR MAKING AND STORING THEM - A composition comprising a high purity cannabinoid, an acid, and a pharmaceutically-acceptable solvent achieves room temperature stability for over 24 months. The acid improves the stability of the composition and the solvent enhances the solubility of the acid, thereby allowing the acid to have an improved stabilizing effect on the highly pure cannabinoid. Preferably, the solvent is an alcohol and, more preferably, the composition contains an oil. A method for making the composition includes combining the cannabinoid and the solvent and evaporating a portion of the solvent, along with adding an acid to the composition, before, during, or after the evaporating step. A method for making and storing the composition includes storing the composition in a manner adapted to maintain its stability. Pharmaceutical dosage forms include a formulated composition, such as having the oil. A method of treating a subject comprises administering to the subject the dosage form. | 2012-10-18 |
20120263786 | Pharmaceutical Formulations Containing an SGLT2 Inhibitor - Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate | 2012-10-18 |
20120263787 | METHOD AND APPARATUS FOR SEALING MEDICINAL CAPSULES - A method of sealing parts of a plastic capsule by forming a weld seam in an overlapping region of the parts of the capsule, wherein the capsule comprises a capsule cap having an open end and a capsule body having an open end, and capsules formed by such method. The capsules produced by the process according to the invention are disposable and preferably contain a single dose of a pharmaceutical formulation in the form of a powder or liquid intended to be administered by inhalation and are suitable by their form and function for use in powder inhalers or liquid nebulizers for producing aerosols. Aerosols thus produced can be inhaled, for example, in order to administer a pharmaceutical formulation to the lungs. | 2012-10-18 |
20120263788 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 2012-10-18 |